Advanced searches left 3/3

Inflammatory Bowel Disease - PubMed

Summarized by Plex Scholar
Last Updated: 08 July 2022

* If you want to update the article please login/register

Molecular basis of vitamin D action in inflammatory bowel disease.

Vitamin D's role in immune regulation and gut barrier function has risen, suggesting that vitamin D may play a vital role in the development of inflammatory bowel disease. Vitamin D and vitamin D receptor signaling in relation to barrier integrity and adaptive/adaptive immunity in the gut, as well as recent findings in determining the biological connection between vitamin D-associated genetic variants and IBD are discussed in this article. Experimental results have uncovered a mechanistic explanation for IBD's pathogenesis by vitamin D. Vitamin D/VDR complex plays a role in the regulation of innate and adaptive immune responses to pathogenic infections in experimental IBD models and IBD patients, contributing to intestinal homeostasis.

Source link: https://doi.org/10.1016/j.autrev.2022.103136


Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era.

BACKGROUND Renal participation can further complicate the course of inflammatory bowel disease. In this review, we sought to determine the presence of renal manifestations in patients with IBD in patients with IBD during the biologic period. RESULTS Of the 1874 patients evaluated, the diagnosis was ulcerative colitis in 1055 patients and Crohn disease in the remaining 819 patients. Both Crohn disease and ulcerative colitis were the most common renal manifestation for Renal calculi. In patients with Crohn disease patients with disease prevalence and surgical resection history, Renal manifestations were attributed to disease exposure and surgical resection history, while no such association was found in patients with ulcerative colitis. CONCLUSIONS Renal manifestations can be seen in up to 6% of patients with IBD, and Crohn disease patients with Crohn disease may be at a greater risk than those with ulcerative colitis. This relationship between IBD and renal manifestations should be considered, particularly when there are no signs of acute renal dysfunction.

Source link: https://doi.org/10.12659/MSM.936497


Patient-reported outcomes for the assessment of sexual health among patients affected by inflammatory bowel disease.

Patients affected by inflammatory bowel disease suffer an impaired quality of sexual health and complain of sexual dysfunctions frequently. Multiple non-IBD-specific questionnaires examining various aspects of sexuality have been applied and validated for the IBD population in real-word studies. This report summarizes the available data on sexual health among IBD patients and the research behind the application of PROs to screen the quality of sexual health among IBD patients, as well as the prevalence and types of sexual dysfunctions among IBD patients.

Source link: https://doi.org/10.2174/1574887117666220630114054


Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.

In both '"step-up" and "top-down" strategies, anti-tumor necrosis factor therapy has been used as a first-line biologic treatment for moderate-to-severe inflammatory bowel disease, and has been a pillar of IBD management. However, in a minority of patients, the effectiveness of anti-TNF therapy is sub-optimal. Drug serum concentrations and the presence of anti-drug antibodies can be determined by therapeutic drug testing, which may help guide treatment selection to achieve patient outcomes. Dose escalation is recommended for patients with low drug traces who are ADAb-negative or have low levels of ADAbs. If ADAb levels are high and the patient has previously received anti-TNF therapy, then switching within class is a viable alternative, as ADAbs are molecule specific. Switching out of class is recommended if a patient does not have a robust therapeutic reaction with an initial anti-TNF despite elevated drug levels.

Source link: https://doi.org/10.3389/fmed.2022.897936


Clinical Characteristics, In Silico Analysis, and Intervention of Neonatal-Onset Inflammatory Bowel Disease With Combined Immunodeficiency Caused by Novel TTC7A Variants.

With combined immunodeficiency due to TTC7A mutations, we wanted to identify the genetic and phenotypic characteristics of neonatal-onset inflammatory bowel disease with combined immunodeficiency. No abnormal splicing in the TTC7A sequence was detected as a result of the c. 2355+4A > G mutation, according to the expression analysis; however, the mRNA expression was reduced; however, no abnormal splicing in the TTC7A sequence was observed in the TTC7A sequence. After initiating leflunomide or methylprednisolone, the proband's health did not improve after receiving methylprednisolone or leflunomide therapy. For the first time, compound heterozygous mutations in the TTC7A gene are described and confirmed. With mixed immunodeficiency, our study extends the phenotypic spectrum of TTC7A mutations and the genotypic spectrum of very early-onset IBD with combined immunodeficiency.

Source link: https://doi.org/10.3389/fgene.2022.921808


Mincle-binding DNA aptamer demonstrates therapeutic potential in a model of inflammatory bowel disease.

Several diseases' progression and appearance have been demonstrated by enhanced signaling of Mincle via the releasing of damage-associated molecular patterns during sterile inflammation. We introduce a highly targeted neutralizing DNA aptamer against Mincle and demonstrate its therapeutic effectiveness. AptMincle selectively binds to both human and mouse Mincle with high affinity, allowing us to specifically target and minimize Mincle activation. AptMincle can reduce trehalose-6,6-dibehenate-induced Syk and P65 phosphorylation in vitro in a manner similar to that of commercially available neutralizing antibodies in vitro. In addition, AptMincleDRBL, a bio-stable modified aptamer, was also effective in reducing disease severity in a dextran sodium sulfate-induced model of ulcerative colitis in a dose- and sequence-dependent manner. The results also show that Mincle-targeted aptamers can be translated into a new category of biologic therapy in the treatment of acute bowel disease.

Source link: https://doi.org/10.1016/j.omtn.2022.05.026


Orally administered covalently-assembled antioxidative peptide nanoparticles for inflammatory bowel disease therapy.

Inflammatory bowel disease is a chronic inflammation disorder that is subjected to a variety of medical difficulties, including inadequate drugs, antibiotic resistance, and systemic toxicology. Covalent assembly of CPP to nanoparticles may be an effective way to maintain the CPP's physiological environment and ultimately improve its ability in vivo antioxidation and IBD therapy.

Source link: https://doi.org/10.1016/j.jcis.2022.06.088

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions